Healthy Participants
Conditions
Keywords
STAT6, STAT6 degrader, targeted protein degrader
Brief summary
This is a Phase I study to evaluate the relative bioavailability and safety and tolerability of different oral formulations of KT-621 in healthy adult participants.
Interventions
DRUGKT-621
KT-621 Reference Oral Formulation
Sponsors
Kymera Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Intervention model description
Parts A and B use an open-label, one-way crossover design in which participants receive KT-621 interventions in a fixed sequence across multiple treatment periods.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants with a weight of at least 50 kilograms (kg) if male or 40 kg if female, and a body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at Screening. * Participants must be willing and able to read, understand, and sign an informed consent form (ICF) which includes compliance with requirements and restrictions listed in the ICF and in this protocol. * Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion criteria
* Participants who have a clinically relevant history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders. * Participants who have a clinically relevant surgical history (for example, surgery of the GI tract that could interfere with the PK of the study medication). Note: prior appendectomy or cholecystectomy is not exclusionary. * Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease. * Participants who have acute GI symptoms at the time of Screening or admission to the CRU (for example, nausea, vomiting, diarrhea, heartburn). * Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening or on admission to the CRU. * Participants who have been dosed with any investigational drug or device in a clinical study within 30 days or 5 half-lives, or time determined by local requirements (whichever is longer) prior to admission to the CRU. * Male participants who do not agree to refrain from sperm donation from admission to the CRU to 90 days after the last dose of KT-621. * Male participants (and their partners of childbearing potential) and female participants who do not agree to the contraception requirements as specified in the clinical protocol. * Female participants who are pregnant, lactating, or breastfeeding, or plan to become pregnant during study participation or within 30 days of the last dose of KT-621. * Female participants with a positive or undetermined pregnancy result at the Screening visit or at admission to the CRU.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Plasma Concentration (Cmax) of KT-621 | Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B) |
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of KT-621 | Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B) |
| Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC∞) of KT-621 | Day 1 through Day 24 (Part A); Day 1 through Day 30 (Part B) |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | From signing of the ICF through the safety follow-up on Day 33 (Part A) or Day 39 (Part B) |
| Incidence of serious adverse events | From signing of the ICF through the safety follow-up visit on Day 33 (Part A) or Day 39 (Part B) |
Countries
United States
Contacts
CONTACTKymera Medical Director
Outcome results
None listed